cell
entri
envelop
virus
requir
widefusionpor
mechan
involv
cluster
fusionactiv
protein
fluidiz
plasma
membran
viral
envelop
present
studi
gl
glycyrrhizin
report
lower
membran
fluiditi
thu
suppress
infect
hiv
influenza
viru
vesicular
stomat
viru
polioviru
gltreat
particl
show
reduc
infect
gl
also
inhibit
celltocel
fusion
induc
htlvi
human
tcell
leukaemia
viru
type
howev
cell
treat
mgml
gl
place
glfree
medium
show
increas
suscept
infect
htlvi
fusion
due
enhanc
membran
fluiditi
membran
depend
gl
gl
remov
experi
suggest
gl
affect
cell
entri
virus
hiv
less
depend
temperatur
less
sensit
gl
treatment
less
indic
exist
molecul
result
higher
probabl
form
cluster
fusionactiv
protein
follow
attach
adsorpt
viral
particl
specif
receptor
host
cell
envelop
virus
must
enter
host
cell
make
fusion
pore
fuse
lipid
bilay
envelop
coat
plasma
cell
membran
fusion
occur
via
least
two
class
viral
protein
envelop
class
model
pertain
influenza
haemagglutinin
fprotein
paramyxovirida
class
ii
involv
e
protein
flavivirida
protein
semliki
forest
viru
essenti
featur
class
protein
format
trimer
helic
coiledcoil
rod
adjac
hydrophob
fusion
peptid
class
ii
fusion
protein
predominantli
nonhel
structur
intern
hydrophob
fusion
loop
loop
insert
outer
leaflet
plasma
membran
enabl
trimer
format
case
cluster
sever
trimer
thought
involv
format
wide
fusion
pore
format
ringlik
assembl
fusion
protein
cooper
membraneinsert
process
observ
studi
rabi
baculoviru
influenza
viru
semliki
forest
viru
celltocel
fusion
cocultiv
htlvi
human
tcell
leukaemia
viru
type
infect
cell
target
cell
also
requir
recruit
viral
envelop
protein
receptor
interfac
virolog
synaps
cellular
fusion
actindepend
energi
transfer
may
associ
assembl
prefus
structur
membran
probabl
facilit
result
later
movement
molecul
via
fluidiz
plasma
membran
plasma
membran
viral
envelop
liquid
disord
physiolog
condit
fluiditi
membran
result
anisotrop
rotat
phopholipid
acyl
chain
flipflop
movement
membran
molecul
quantit
measur
fluiditi
live
cell
plasma
membran
viral
particl
envelop
esr
use
stearic
acid
correl
infect
fluiditi
observ
follow
heat
treatment
fluiditi
modul
deterg
xylocain
phosphatidylcholin
dipalmitoyl
decreas
fluiditi
suppress
infect
wherea
increas
enhanc
infect
fluiditi
envelop
alway
lower
plasma
membran
sinc
cholesterolprotein
ratio
viral
envelop
higher
plasma
membran
sterol
cholesterol
serv
essenti
function
eukaryot
plasma
membran
propos
excess
cholesterol
lead
liquidord
rigid
phase
plasma
membran
bilay
liquiddisord
phase
small
chang
plasma
membran
cholesterol
level
near
physiolog
set
point
might
evok
larg
biolog
respons
thu
conceiv
cholesterol
cholesterollik
substanc
associ
plasma
membran
andor
viral
envelop
may
play
neg
role
format
larg
cluster
fusion
protein
creat
fusion
pore
find
hypothes
form
basi
present
studi
sinc
gl
glycyrrhizin
activ
compon
liquoric
root
similar
molecular
structur
cholesterol
figur
effect
fluiditi
plasma
membran
viral
envelop
investig
moreov
gl
report
previous
show
broad
antivir
activ
envelop
virus
vaccinia
herp
simplex
viru
type
newcastl
diseas
vsv
vesicular
stomat
viru
vzv
varicellazost
viru
measl
sar
sever
acut
respiratori
syndrom
virus
inhibit
viral
infect
gl
report
shown
mostli
due
suppress
fluiditi
plasma
membran
viral
envelop
gl
incorpor
effect
fluiditi
readili
revers
gl
withdrawn
cultur
studi
propos
new
antivir
strategi
directli
suppress
fluiditi
lipid
bilay
membran
inhibit
format
fusion
pore
one
host
factor
import
control
envelop
viral
entri
avail
gl
clinic
set
also
discuss
cell
cultur
rpmi
medium
supplement
vv
heatinactiv
fb
fetal
bovin
serum
antibiot
fl
mdck
cell
cultur
dulbecco
modifi
eagl
medium
vv
fb
antibiot
describ
previous
plaqueclon
virus
lai
strain
obtain
cultur
supernat
chronic
infect
cell
jrfl
virus
vaccin
strain
type
polioviru
propag
infect
fl
cell
respect
cultur
day
filtr
membran
supernat
store
c
jrfl
vsvenvelopepseudotyp
virus
luciferas
report
gene
design
jrflluc
vsvg
pseudovirus
respect
produc
calcium
phosphat
transfect
method
hek
cell
cotransfect
envelopedefici
construct
carri
luciferas
gene
vector
express
envelop
glycoprotein
pseudotyp
virus
jrfl
vsv
envelop
glycoprotein
produc
cotransfect
pcxnflenv
phcmvg
plasmid
respect
cell
cultur
day
supernat
harvest
filter
store
c
influenza
virus
influenza
kindli
provid
dr
akaik
depart
microbiolog
kumamoto
univers
kumamoto
japan
gl
acid
minophagen
pharmaceut
co
dissolv
pb
concentr
mgml
mm
store
c
sigmaaldrich
store
concentr
mgml
ethanol
c
verapamil
sigmaaldrich
store
concentr
mm
pb
c
cytotox
cell
observ
concentr
mm
mgml
gl
verapamil
express
level
cell
unalt
treatment
mgml
gl
verapamil
ml
volum
cell
ml
cultur
supernat
contain
mix
ml
ml
pb
respect
give
final
concentr
incub
c
min
remov
free
spin
label
pellet
cell
virus
resuspend
pb
without
mgml
gl
drawn
capillari
tube
capillari
tube
place
quartz
glass
tube
spectra
record
use
esr
spectromet
jeol
ltd
tokyo
japan
c
instrument
condit
min
scan
time
mt
sweep
width
mt
field
modul
width
mw
microwav
power
time
constant
figur
show
repres
spectra
outer
hyperfin
split
indic
inner
one
denot
horizont
axi
reflect
vari
magnet
field
vertic
axi
repres
absorpt
microwav
order
paramet
calcul
follow
gl
mostli
ad
cultur
viral
adsorpt
cell
mix
virus
absenc
presenc
serial
dilut
gl
c
h
subsequ
cell
wash
cultur
c
infect
assess
experi
cell
virus
treat
serial
dilut
gl
c
h
free
gl
remov
centrifug
glpretreat
cell
virus
use
viral
adsorpt
c
h
wash
cell
cultur
c
portion
cell
cell
mix
ml
absenc
presenc
serial
dilut
gl
incub
c
h
wash
cell
cultur
c
day
h
respect
cell
smear
glass
slide
fix
vv
mixtur
cold
methanol
aceton
c
min
infect
cell
stain
indirect
method
describ
previous
assess
infect
jrfl
cell
use
target
cell
cell
per
sampl
count
calcul
percentag
jrflposit
cell
percentag
infect
calcul
posit
cell
test
posit
cell
control
cell
cellswel
seed
previou
day
flat
plate
infect
jrflluc
respect
absenc
presenc
serial
dilut
gl
viral
adsorpt
took
place
c
h
wash
plate
incub
c
day
infect
cell
lyse
luciferas
assay
buffer
promega
madison
wi
usa
luciferas
activ
measur
describ
previous
fl
cell
concentr
cellswel
flat
plate
use
target
cell
vsvg
pseudoviru
haemadsorpt
test
mdck
cell
cellswel
place
flat
plate
cultur
c
overnight
cell
treat
mixtur
influenza
viru
serial
dilut
gl
c
h
wash
cultur
c
h
plate
wash
pb
mlwell
vv
red
blood
cell
ad
well
plate
incub
room
temperatur
min
wash
extens
three
time
pb
haemadsorb
cell
per
well
count
microscop
tcid
tissu
cultur
infecti
dose
fl
cell
cellswel
seed
previou
day
flat
plate
infect
serial
dilut
polioviru
absenc
presenc
serial
dilut
gl
hexad
viral
adsorpt
carri
c
h
plate
incub
c
day
wash
well
show
cytopath
effect
count
microscop
tcid
dilut
gl
calcul
use
reedmuench
method
htlvitransform
cell
use
target
effector
cell
respect
fusion
assay
absenc
presenc
gl
ml
cell
cell
mix
amount
cell
experi
cell
type
treat
separ
gl
c
h
wash
mix
mixtur
mlwell
place
flat
plate
cultur
c
h
fuse
balloon
cell
per
one
field
microscop
count
ultracentrifug
use
pellet
ng
jrflluc
pseudovirus
lyse
ad
lysi
buffer
describ
previous
viral
lysat
resolv
sdspolyacrylamid
gel
blot
pvdf
membran
atto
corpor
tokyo
japan
block
nonspecif
bind
membran
incub
dilut
serum
c
h
wash
three
time
incub
antihuman
igg
conjug
alkalin
phosphatas
sigma
reaction
detect
chromat
use
alkalin
phosphataselink
reagent
accord
standard
techniqu
amount
core
assess
use
antigen
elisa
cellular
product
buffalo
ny
usa
accord
manufactur
protocol
statist
analys
carri
use
student
unpair
test
p
valu
consid
indic
statist
signific
fluidiz
lipidbilay
examin
incorpor
spin
probe
live
cell
membran
viral
particl
envelop
esr
spectra
record
c
figur
order
paramet
valu
calcul
esr
spectra
order
paramet
repres
anisotrop
motion
long
molecular
axi
spinlabel
probe
thu
invers
indic
flexibl
incorpor
probe
treatment
cell
mgml
gl
increas
order
paramet
respect
figur
fluiditi
membran
dose
depend
suppress
gl
order
paramet
mgml
gltreat
also
higher
untreat
figur
thu
gl
significantli
suppress
fluiditi
plasma
membran
viral
envelop
cell
virus
incub
c
h
mgml
gl
subject
esr
effect
gl
infect
examin
target
cell
incub
virus
presenc
serial
dilut
gl
viral
adsorpt
c
h
figur
show
ec
gl
mgml
cell
infect
plaqueclon
viru
lai
strain
cell
stain
count
use
indirect
method
similarli
vzv
gltreat
virus
show
significantli
decreas
infect
cell
indic
gl
affect
cell
also
viral
particl
similar
inhibitori
effect
gl
ec
mgml
observ
cell
use
viru
infect
instead
cell
ec
mgml
gl
obtain
infect
cell
strain
jrfl
virus
figur
thu
gl
equal
effect
figur
ghost
figur
cell
infect
also
investig
use
replicationdefect
viru
pseudotyp
envelop
viru
case
sinc
viru
replic
cell
luciferas
activ
correl
abil
viru
penetr
target
cell
singleround
infect
experi
show
ec
mgml
cell
incub
concomitantli
viru
serial
dilut
gl
adsorpt
period
infect
gltreat
virus
cell
also
decreas
dosedepend
fashion
howev
effect
seen
cell
weaker
cell
impli
gl
incorpor
pseudotyp
viru
particl
could
imped
entranc
target
cell
unexpectedli
pretreat
cell
gl
almost
effect
viru
infect
effici
contrast
cell
exhibit
enhanc
infect
case
mgml
glpretreat
ghost
cell
respect
gl
inhibit
infect
influenza
viru
pseudotyp
viru
vsvg
envelop
ec
valu
approx
mgml
mgml
respect
figur
show
effect
polioviru
infect
figur
toxic
cell
observ
mgml
mm
gl
chang
express
cell
detect
mgml
gl
result
shown
sinc
viral
product
amount
chronic
infect
cell
unaffect
treatment
mgml
gl
effect
gl
infect
due
level
transcript
provir
dna
gl
inhibit
balloon
degener
fuse
cell
gl
continu
present
cultur
medium
use
cocultiv
cell
target
cell
figur
figur
also
show
htlvitransform
cell
cocultur
cell
balloonedfus
cell
also
observ
figur
almost
complet
absent
presenc
mgml
gl
figur
thu
celltocel
fusion
induc
htlvi
also
strongli
inhibit
continu
presenc
mgml
gl
howev
cellfre
infect
system
gl
pretreat
effector
cell
target
cell
enhanc
fusion
figur
number
balloonedfus
cell
increas
cell
pretreat
mgml
gl
figur
lane
time
cell
pretreat
figur
lane
enhanc
viral
infect
cell
fusion
explain
due
block
attach
viral
ligand
molecul
cellsurfac
receptor
cover
steric
hindranc
effect
gl
fluiditi
modif
gl
respons
suppress
augment
infect
fusion
hypothes
fluiditi
alter
gl
remov
medium
kinet
membran
fluiditi
examin
time
gl
wash
away
cell
figur
gluntreat
cell
show
rel
stabl
fluiditi
cell
resuspend
mgml
gl
pb
glwash
continu
gltreat
cell
kept
high
order
paramet
contrast
cell
resuspend
pb
wash
gl
glpretreat
cell
exhibit
order
paramet
min
wash
rapidli
decreas
min
wash
thereaft
gradual
increas
reach
valu
note
paramet
glpretreat
cell
min
alway
lower
untreat
control
cell
kinet
indic
gl
readili
diffus
plasma
membran
obtain
equilibrium
outsid
gl
concentr
quickli
diffus
membran
gl
remov
medium
kinet
viru
envelop
fluiditi
figur
somewhat
differ
plasma
membran
fluiditi
figur
untreat
continu
gltreat
virus
kept
low
high
level
order
paramet
respect
order
paramet
glpretreat
envelop
also
decreas
min
gl
wash
paramet
alway
continu
gltreat
untreat
virus
gl
might
equilibr
across
membran
simpl
diffus
although
gl
movement
may
passiv
consequ
chemic
hydrophil
lipophil
properti
possibl
flip
movement
pglycoprotein
excret
gl
plasma
membran
examin
verapamil
flippas
inhibitor
bind
directli
pglycoprotein
competit
inhibit
drug
transport
treatment
cell
verapamil
result
slight
signific
increas
membran
fluiditi
figur
consequ
infect
enhanc
figur
effect
infect
cell
observ
less
verapamil
howev
glpretreat
cell
treat
verapamil
use
target
cell
infect
addit
enhanc
figur
fluiditi
glpretreat
cell
treat
verapamil
increas
greatli
time
show
lower
paramet
glpretreat
cell
time
point
measur
figur
least
verapamil
block
effect
induc
pretreat
gl
altern
data
may
indic
minim
chang
membran
fluiditi
induc
gl
verapamil
influenc
infect
mechan
gl
increas
fluiditi
may
differ
verapamil
ec
valu
jrflluc
pseudoviru
mgml
respect
gl
figur
appar
jrflluc
viral
prepar
resist
effect
gl
divid
luciferas
activ
figur
amount
untreat
jrflluc
virus
allow
viral
infect
singl
viral
particl
assum
equal
quaniti
per
viral
particl
calcul
result
indic
jrflluc
viru
ng
almost
ten
time
higher
infect
per
one
viral
particl
viru
ng
effect
temperatur
anoth
fluiditymodifi
factor
infect
jrflluc
virus
figur
also
examin
viral
adsorpt
carri
c
c
c
h
viral
infect
depend
temperatur
infect
viru
increas
time
c
c
time
c
c
contrast
infect
jrflluc
enhanc
time
c
c
time
c
c
thu
highli
infecti
jrflluc
virus
resist
gl
less
depend
temperatur
western
blot
analysi
show
per
detect
jrflluc
virus
figur
augment
infect
increas
amount
virion
report
suggest
multiplesit
bind
receptor
requir
complet
infect
theoret
exist
molecul
viral
particl
could
result
higher
probabl
form
cluster
activ
fusion
peptid
due
multiplesit
bind
regardless
level
fluiditi
could
explain
jrflluc
viru
resist
effect
gl
less
depend
temperatur
viru
gl
broad
antivir
agent
block
infect
vaccinia
newcastl
diseas
vsv
figur
vzv
measl
figur
sar
influenza
figur
virus
polioviru
figur
ec
valu
sar
viru
vsv
influenza
viru
approx
mgml
gl
may
act
lipid
bilay
membran
sinc
firstli
singleround
infect
system
pseudoviru
use
effect
secondli
gl
act
revers
h
viral
adsorpt
thirdli
pretreat
figur
vzv
particl
gl
reduc
infect
fact
gl
decreas
fluiditi
plasma
membran
viral
envelop
figur
minim
chang
membran
fluiditi
logarithm
respons
infect
plausibl
reduct
fluiditi
gl
primari
mechan
caus
inhibit
viral
infect
propos
membran
envelop
fluiditi
play
pivot
role
format
wide
fusion
pore
envelop
virus
cluster
substanti
number
activ
viral
fusion
protein
deriv
multipl
ligandreceptor
complex
respect
gl
mainli
act
envelop
virus
addit
reduc
fluiditi
gl
could
easili
explain
gl
inhibit
celltocel
fusion
induc
htlvi
figur
suppress
format
virolog
synaps
gltreat
cell
wash
replac
medium
glfree
fluiditi
membran
increas
time
figur
cell
show
enhanc
suscept
infect
figur
fusion
figur
factor
regul
format
wide
fusion
pore
number
receptor
number
molecul
degre
fluiditi
cell
mixtur
carri
varieti
receptor
molecul
variou
amount
viral
stock
also
consist
mixtur
virus
bear
variabl
amount
cell
receptor
virus
molecul
could
form
cluster
contain
substanti
number
activ
viral
fusion
protein
deriv
multiplesit
bind
howev
increas
fluiditi
could
promot
suffici
multiplesit
bind
thu
enhanc
suscept
viral
infect
fusion
degre
fluiditi
parallel
infect
fusion
els
could
explain
observ
antiand
activ
tradit
interpret
rule
nonspecif
inhibit
viral
adsorpt
polyanion
compound
reduct
cell
signal
use
pathway
protein
kinas
c
induct
interferon
vivo
product
nitrou
oxid
macrophag
fail
account
gl
activ
especi
action
one
mechan
found
fulli
explain
antiand
phenomena
direct
modul
lipid
bilay
membran
fluiditi
gl
gl
could
prevent
promot
rapid
access
fusion
protein
receptor
modifi
pore
widen
full
fusion
viru
entri
altern
gl
may
impair
curvatur
membran
necessari
format
fusion
pore
howev
latter
possibl
littl
fluiditi
gl
seem
diffus
easili
across
lipid
bilay
membran
high
concentr
gl
insid
membran
restrict
anisotrop
movement
acyl
chain
likewis
phospholipid
thu
gl
lower
fluidiz
plasma
membran
viral
envelop
contrast
cell
wash
gltreatment
fluidiz
increas
probabl
due
rapid
reduct
gl
content
insid
membran
rapid
gl
diffus
membran
might
induc
flexibl
acyl
chain
enhanc
fluiditi
glpretreat
cell
due
increas
flipflop
movement
pglycoprotein
flippas
inhibitor
verapamil
block
either
enhanc
fluiditi
increas
infect
induc
gl
pretreat
cell
anyth
treatment
verapamil
slightli
enhanc
fluiditi
infect
show
addit
effect
gl
pretreat
cell
confirm
fluiditi
may
play
major
role
infect
virus
less
sensit
gl
treatment
less
figur
also
less
depend
temperatur
indic
gl
effect
membran
temperatur
exist
molecul
viru
could
result
higher
probabl
form
cluster
activ
fusion
peptid
multiplesit
bind
regardless
level
fluiditi
respect
gl
virostat
agent
virocid
advantag
gl
broad
antivir
agent
side
effect
although
data
safeti
longterm
usag
high
dose
gl
still
need
collect
best
exampl
safeti
long
histori
safe
use
clinic
set
japan
disadvantag
gl
use
high
concentr
exhibit
antivir
activ
virostat
hiv
infect
could
inhibit
pharmacolog
achiev
concentr
gl
low
toxic
clinic
trial
longterm
use
drug
would
unrealist
except
case
uncontrol
resist
virus
emerg
antihiv
agent
rather
one
would
predict
topic
applic
high
dose
gl
would
invalu
prevent
sexual
transmit
infect
hiv
also
hsv
base
abil
gl
inhibit
infect
influenza
figur
sar
vaccinia
virus
vsv
suggest
compound
might
appropri
drug
access
treatment
emerg
acut
lethal
infect
new
type
influenza
sar
rabi
smallpox
virus
sinc
gl
directli
affect
viral
envelop
reduc
viral
infect
rate
nosocomi
infect
could
also
reduc
approach
especi
attract
sinc
gl
exert
pharmacodynam
action
lipid
bilay
membran
cell
viru
therefor
broad
antivir
potenti
side
effect
discoveri
new
mode
action
gl
offer
addit
opportun
systemat
screen
access
chemic
compound
glycolipid
membranefluid
modul
might
provid
common
therapeut
intervent
wide
rang
virus
potenti
new
highli
effect
applic
